סרוקואל 400 מג XR ישראל - עברית - Ministry of Health

סרוקואל 400 מג xr

astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 400 mg - quetiapine

קוסליוגו 10 מג ישראל - עברית - Ministry of Health

קוסליוגו 10 מג

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 10 mg - selumetinib

קוסליוגו 25 מג ישראל - עברית - Ministry of Health

קוסליוגו 25 מג

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 25 mg - selumetinib

קסיגדו 10 מג 1000 מג XR ישראל - עברית - Ministry of Health

קסיגדו 10 מג 1000 מג xr

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 1005.04 mg; dapagliflozin propanediol 12.30 mg - metformin and dapagliflozin

קסיגדו 10 מג 500 מג XR ישראל - עברית - Ministry of Health

קסיגדו 10 מג 500 מג xr

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 12.30 mg - metformin and dapagliflozin

קסיגדו 5 מג 1000 מג XR ישראל - עברית - Ministry of Health

קסיגדו 5 מג 1000 מג xr

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 1005.04 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin

קסיגדו 5 מג 500 מג XR ישראל - עברית - Ministry of Health

קסיגדו 5 מג 500 מג xr

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin

נקסיום טבליות 20 מג ישראל - עברית - Ministry of Health

נקסיום טבליות 20 מג

astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.

נקסיום טבליות  40 מג ישראל - עברית - Ministry of Health

נקסיום טבליות 40 מג

astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.

אונגלייזה 5 מג ישראל - עברית - Ministry of Health

אונגלייזה 5 מג

astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.